Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains.
Overview
On June 11, 2026, Christian Heidbreder, Chief Scientific Officer at Indivior Pharmaceuticals (NASDAQ:INDV), reported the sale of 18,586 shares of common stock in an open-market transaction, as detailed in the SEC Form 4 filing.
Transaction value based on SEC Form 4 reported price ($38.06); post-transaction value based on June 11, 2026 market close ($38.13).
Details
* 1-year performance calculated using June 11, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.